Platelet derived Growth Factor AA (PDGF-AA), Human Recombinant
10 µg
$150.00
Skip to product information
Platelet derived Growth Factor AA (PDGF-AA), Human Recombinant
Catalog no.
GF-080-3
$150.00
Human PDGF-AA homodimer is produced by genetically engineered yeast, and purified by ionic exchange chromatography and reverse-phase HPLC. This polypeptide is composed of two identical polypeptide chains attached by disulfide bonds.
- Purity: Over 95% pure by N-terminal amino acid sequencing, amino acid composition, HPLC analysis, and SDS gel electrophoresis.
- Storage: Store at +4°C. Reconstitution is best in water or buffer near neutral pH.
- Stability: Several months at +4°C.
- Biological activity: Thematerial is fully active as measured by the mitogenic assay involving the stimulation of 3H-thymidine incorporation into NIH-3T3 cells.
- Formulation: Lyophilized powder
-
References:
1. Heldin, C.H. and Westmark, B. (1990) Celll Regul. 1: 555-566
2. Raines, E. W. et al. (1990) Handbook of Experimental Pharmacology (Sporn, M.B. and Roberts, A.B. eds) Vol 9i5: pages 173-262
3. Ostman, A. et al. (1989) Growth Factors 1: 219-229
Publications using Austral Biologicals GF-080
The following scientific publications report use of PDGF-AA from Austral Biologicals:
- Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α. Lowery et al., Clinical Cancer Research 24 847-857 (2018).
- Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay. Schwickart et al., Journal of Immunological Methods 403 52-61 (2014).
- LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Yan et al., Investigational New Drugs 31 833-844 (2013).
- Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target. Loizos et al., Molecular Cancer Therapeutics 4 369-379 (2005).
- Platelet‐derived growth factor causes endothelium‐independent relaxation of rabbit mesenteric artery via the release of a prostanoid. Yamawaki et al., British Journal of Pharmacology 131 1546-1552 (2000).
- PDGF-α Receptor Subunit Expression Down-regulated by IL-1β in Human Periodontal Ligament Cells. Oates et al., Journal of Dental Research 77 1791-1798 (1998).
- Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. Yashiro et al., British Journal of Cancer 74 1096-1103 (1996).
- Pro-inflammatory cytokines downregulate platelet derived growth factor-α receptor gene expression in human osteoblastic cells. Kose et al., Journal of Cellular Physiology 166 188-197 (1996).
- PDGFs protect hippocampal neurons against energy deprivation and oxidative injury: evidence for induction of antioxidant pathways. Cheng et al., The Journal of Neuroscience 15 7095-7104 (1995).
- Platelet-derived growth factors-AA and -BB regulate collagen and collagenase gene expression differentially in human fibroblasts. Tan et al., Biochemical Journal 310 585-588 (1995).
- Receptor binding of PDGF‐AA and PDGF‐BB, and the modulation of PDGF receptors by TGF‐β, in human periodontal ligament cells. Oates et al., Journal of Cellular Physiology 162 359-366 (1995).
- Interleukin-1 modulates phosphorylation of proteins in human osteoblastic cells. Kang et al., Journal of Bone and Mineral Research 10 96-105 (1995).